Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 4,731 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Signs and Symptoms, Respiratory Clear all

Conditions: COVID-19
Interventions: Clazakizumab, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Snoring
Interventions: nasal continuous positive airway pressure less than or equal to 6 cm H2O; Device
Lead sponsor: inSleep Technologies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Lanham, Maryland

Conditions: HIV Infections, COPD, Microbiome
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lung Diseases, Medication Compliance
Interventions: Fluticasone propionate 230mcg for 3 Months, Current Treatment or no treatment, Salmeterol 21mcg for 3 Months; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Long COVID
Interventions: Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc, Placebo, Atorvastatin; Drug
Lead sponsor: HealthBio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Metastatic Solid Tumor, Non-Small Cell Lung Carcinoma, Esophageal Adenocarcinoma, SMARCA4 Mutation, Gastroesophageal Junction Squamous Cell Carcinoma, Advanced Solid Tumor
Interventions: PLX-61639; Drug
Lead sponsor: Plexium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Scottsdale, Arizona • Duarte, California • Orange, California + 7 more

Conditions: Asthma, Obesity
Interventions: Better asthma self-management and incorporation of physical activity, Asthma Education; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years to 64 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Sleep Apnea Syndromes
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,685 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Asthma
Interventions: QAW039, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 55
States / cities: Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 49 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: Indacaterol/Glycopyrrolate, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years to 80 Years
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Cachexia
Interventions: GSK2881078, Matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Torrance, California • Jacksonville, Florida • High Point, North Carolina + 2 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BGF; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 3,402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Apnea
Interventions: Subject using usual positive airway pressure therapy while sleeping for one night; Other
Lead sponsor: Heidi Roth, MD; Other
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Respiratory Distress Syndrome, Adult
Interventions: BIO-11006, Placebo; Drug
Lead sponsor: BioMarck Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Chicago, Illinois • Chapel Hill, North Carolina • Winston-Salem, North Carolina + 2 more

Conditions: Surgical Complication, COVID-19, Pneumothorax, Empyema, Pleural, Abscess, Hemothorax, Thoracic
Interventions: Lung parenchyma resection, Empyemectomy; Procedure
Lead sponsor: University of Milano Bicocca; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Cerebral Palsy, Hypoxia, Brain
Interventions: Aquatic therapy; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 3 Years to 9 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: COPD, Smoking, Tobacco Use
Interventions: Cigarette, THS; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 40 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 46
States / cities: Clearwater, Florida • Coral Gables, Florida • Davie, Florida + 24 more

Conditions: Pulmonary Disease, Chronic Obstructive, Emphysema
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 35 Years to 90 Years
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: COPD
Interventions: Arformoterol tartrate inhalation solution, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 31
States / cities: Encinitas, California • Long Beach, California • Brandon, Florida + 28 more

Conditions: Esophageal Atresia, Tracheoesophageal Fistula
Interventions: Transanastomotic Tube (5FR), No Transanastomotic Tube; Device · Other
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: Up to 6 Months
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 7 more

Conditions: Head Cancer, Neck Cancer, Pain
Interventions: Transcutaneous Electrical Nerve Stimulation (TENS); Device
Lead sponsor: Jennifer E. Lee; Other
Eligibility: 18 Years to 90 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Cystic Fibrosis, Respiratory Tract Infections
Interventions: Cholecalciferol; Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 16 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 5
States / cities: Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 2 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Self-Management Intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Sarcoidosis, Pulmonary
Interventions: Pirfenidone, Placebos; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

Study of Nasal Airflow Pressure Optimization to Resolve Excessive Snoring

Dysbiosis Impact on Lung Disease in HIV

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Asthma and Obesity: Pilot Study

Snoring in Pregnancy and Adverse Maternal and Fetal Outcomes

Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)

Sleep Apnea and Visual Perceptual Skill Learning

Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

The Role of Surgery in Patients With Coronavirus Disease - 19 (COVID-19) Related Thoracic Complications

Aquatic Therapy for Children With Neuromotor Deficits

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS

Evaluating the Effects of Surgical and Non-Surgical Treatment Options in People With Emphysema

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Transanastomotic Tube for Proximal Esophageal Atresia With Distal Tracheoesophageal Fistula Repair

Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)

Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)

The Effects of a Self-management Intervention on Low Literacy Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pirfenidone for Progressive Fibrotic Sarcoidosis